Medication info
Ongliza Tablet 5 mg (Saxagliptin Hydrate)

Ongliza Tablet 5 mg (Saxagliptin Hydrate)

Prescription medicationTabletOral
Ingredient · strength
Saxagliptin Hydrate›5.29mg / 1 tablet
Manufacturer / importer
AstraZeneca Korea
Appearance
Pink, round, film-coated tablet with a biconvex shape
Packaging
28 tablets (14 tablets/PTP x 2)
Approval status
Active

MFDS item code 201100373 · Approved 2011.01.24 · Insurance code 650700880

Summary

Main use
Improvement of glycemic control in type 2 diabetes mellitus
Who takes it
Adults
Adult dose
1. When administered as monotherapy, the recommended dose of this drug is 2.5mg or 5mg once daily. 2. When administered in combination therapy - For patients with no prior experience of antidiabetic drug treatment who do not achieve adequate glycemic control with monotherapy, the recommended dose of this drug when administered in combination with metformin is 5mg once daily. - For patients who do not achieve adequate glycemic control with metformin, a sulfonylurea, or a thiazolidinedione as monotherapy, the recommended dose of this drug when administered in combination is 2.5mg or 5mg once daily. - For patients who do not achieve adequate glycemic control with combination therapy of metformin and a sulfonylurea, the recommended dose of this drug when administered in combination is 5mg once daily. - For patients who do not achieve adequate glycemic control with insulin therapy (insulin alone or in combination with metformin), the recommended dose of this drug when administered in combination is 5mg once daily. - For patients who do not achieve adequate glycemic control with combination therapy of metformin and dapagliflozin, the recommended dose of this drug when administered in combination is 5mg once daily. This drug may be administered regardless of meals and should not be cut or divided. Patients with renal impairment: - Patients with mild renal impairment (eGFR ≥45mL/min/1.73 m2): No dose adjustment is required. - Patients with moderate or severe renal impairment, or end-stage renal disease requiring hemodialysis (eGFR <45mL/min/1.73 m2): Administer 2.5mg once daily. This drug should be administered after hemodialysis and has not been studied in patients receiving peritoneal dialysis. Since dose adjustment may be required according to renal function, assessment of renal function is recommended before starting this drug and periodically during treatment. When administered in combination with a strong cytochrome P450 3A4/5 inhibitor: Administer 2.5mg once daily. (See section ‘5. Interactions’ under Precautions for Use.) When administered in combination with insulin or an insulin secretagogue (such as a sulfonylurea), a lower dose of insulin and the insulin secretagogue may be needed to minimize the risk of hypoglycemia.

Ingredients

Importer
AstraZeneca Korea

Efficacy & effects

Improvement of glycemic control in type 2 diabetes mellitus

View approved original text

This medication helps improve blood sugar control in patients with type 2 diabetes. It is effective for blood sugar management when used in conjunction with dietary and exercise therapy, and can be administered alone or in combination with other medications. This facilitates smooth blood sugar control and contributes to diabetes treatment.

How to take

Adult dose

1. When administered as monotherapy, the recommended dose of this drug is 2.5mg or 5mg once daily. 2. When administered in combination therapy - For patients with no prior experience of antidiabetic drug treatment who do not achieve adequate glycemic control with monotherapy, the recommended dose of this drug when administered in combination with metformin is 5mg once daily. - For patients who do not achieve adequate glycemic control with metformin, a sulfonylurea, or a thiazolidinedione as monotherapy, the recommended dose of this drug when administered in combination is 2.5mg or 5mg once daily. - For patients who do not achieve adequate glycemic control with combination therapy of metformin and a sulfonylurea, the recommended dose of this drug when administered in combination is 5mg once daily. - For patients who do not achieve adequate glycemic control with insulin therapy (insulin alone or in combination with metformin), the recommended dose of this drug when administered in combination is 5mg once daily. - For patients who do not achieve adequate glycemic control with combination therapy of metformin and dapagliflozin, the recommended dose of this drug when administered in combination is 5mg once daily. This drug may be administered regardless of meals and should not be cut or divided. Patients with renal impairment: - Patients with mild renal impairment (eGFR ≥45mL/min/1.73 m2): No dose adjustment is required. - Patients with moderate or severe renal impairment, or end-stage renal disease requiring hemodialysis (eGFR <45mL/min/1.73 m2): Administer 2.5mg once daily. This drug should be administered after hemodialysis and has not been studied in patients receiving peritoneal dialysis. Since dose adjustment may be required according to renal function, assessment of renal function is recommended before starting this drug and periodically during treatment. When administered in combination with a strong cytochrome P450 3A4/5 inhibitor: Administer 2.5mg once daily. (See section ‘5. Interactions’ under Precautions for Use.) When administered in combination with insulin or an insulin secretagogue (such as a sulfonylurea), a lower dose of insulin and the insulin secretagogue may be needed to minimize the risk of hypoglycemia.

Precautions

This medication should not be used by certain patients. For example, patients who have shown serious allergic reactions to this medication or other DPP-4 inhibitors, as well as those with type 1 diabetes or diabetic ketoacidosis, should not take this medication. Additionally, patients with lactose intolerance or genetic lactase deficiency should also refrain from using this medication. Caution is required when this medication is used with other drugs that may cause hypoglycemia. Particularly, the risk of hypoglycemia increases when combined with insulin or sulfonylureas, so dosage adjustments may be necessary. In patients with heart failure, this medication should be administered carefully and is not recommended for patients with severe heart failure. Symptoms of heart failure that arise during treatment should be reported to a healthcare professional immediately. Acute pancreatitis has been reported, so careful observation for symptoms of pancreatitis is necessary, and if suspected, the medication should be discontinued immediately. Hypersensitivity reactions, such as anaphylaxis or angioedema, may occur, so if such symptoms appear, the use of this medication should be stopped and a healthcare professional should be consulted. Since this medication is primarily excreted through the kidneys, dosage adjustments may be needed for patients with impaired kidney function, and elderly patients should also be monitored based on kidney function. Women who are pregnant or nursing should exercise caution when using this medication and should consult a professional if necessary. While taking this medication, headaches, upper respiratory infections, urinary tract infections, gastrointestinal symptoms, etc., may occur, so any persistent symptoms should be reported to a healthcare professional. Additionally, caution is needed while driving or operating machinery due to the possibility of drowsiness. In cases of overdose, there is no specific antidote, and general treatment will be provided according to symptoms, with some medications able to be removed through hemodialysis. The safety and efficacy of this medication in children have not been established, so it is advisable not to use it. Finally, this medication should be stored in its original container and kept out of reach of children.

Side effects

  • Anaphylaxis
  • angioedema
  • hypoglycemia
  • acute pancreatitis
  • lymphocytopenia
  • headache
  • upper respiratory tract infection
  • urinary tract infection
  • sinusitis
  • abdominal pain
Show 80 more
  • gastroenteritis
  • vomiting
  • peripheral edema
  • rash
  • urticaria
  • tuberculosis
  • salmonella sepsis
  • severe arthritis with disability
  • bullous pemphigoid
  • dizziness
  • vertigo
  • paresthesia
  • increased sputum
  • cold
  • hemoptysis
  • bronchitis
  • rhinitis
  • asthma
  • runny nose
  • emphysema
  • pneumonia
  • hyperglycemia
  • weight loss
  • weight gain
  • arthralgia
  • arthritis
  • musculoskeletal chest pain
  • myopathy
  • back pain
  • generalized pain
  • sciatica
  • erythromelalgia
  • eczema
  • skin disorders
  • burns
  • pruritus
  • cystitis
  • acute renal failure
  • dysuria
  • painful urination
  • kidney stones
  • neurogenic bladder
  • pyelonephritis
  • hypertension
  • heart failure
  • cardiomegaly
  • insomnia
  • depression
  • acute stress reaction
  • anxiety
  • drowsiness
  • amenorrhea
  • vulvitis
  • uterine bleeding
  • vaginitis
  • menopausal symptoms
  • glaucoma
  • macular degeneration
  • herpes zoster
  • parasitic infection
  • viral infection
  • myocardial infarction
  • stroke
  • subarachnoid hemorrhage
  • vasculitis
  • increased SGPT
  • increased SGOT
  • fatty liver
  • palpitations
  • arrhythmia
  • febrile neutropenia
  • tinnitus
  • soft tissue inflammation
  • taste changes
  • bone metastasis
  • laceration
  • joint dislocation
  • diarrhea
  • hypotension
  • diabetic retinopathy

Not everyone experiences these, and they can vary from person to person.

Storage

This medication should be stored in a tightly closed container to protect it from air and moisture. Additionally, it is best to store the medication at room temperature between 1°C and 30°C.

Appearance and packaging

Appearance

Pink, round, film-coated tablet with a biconvex shape

Package unit

28 tablets (14 tablets/PTP x 2)

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.